Carrier risk status changes resulting from mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast-ovarian cancer

被引:26
作者
Watson, P
Narod, SA
Fodde, R
Wagner, A
Lynch, JF
Tinley, ST
Snyder, CL
Coronel, SA
Riley, B
Kinarsky, Y
Lynch, HT
机构
[1] Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE 68178 USA
[2] Ctr Res Womens Hlth, Toronto, ON, Canada
[3] Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands
[4] Erasmus Univ, Med Ctr, Dept Clin Genet, Rotterdam, Netherlands
关键词
D O I
10.1136/jmg.40.8.591
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Context: In hereditary cancer syndrome families with an identified cancer associated mutation, mutation testing changes the carrier risk status of the tested person and may change the carrier risk status of relatives. Objective: This study aimed to describe the change in the distribution of carrier risk status resulting from testing in hereditary breast-ovarian cancer (HBOC) and hereditary non-polyposis colorectal cancer (HNPCC) families. Design: This was an observational cohort study. Patients: The cohort included members of 75 HBOC and 47 HNPCC families. Of the 10 910 cohort members, 1408 were tested for a mutation and learned their test results. Outcome measure: Carrier risk for all cohort members was assessed before and after mutation testing. Results: There was a change in carrier risk status in 2906 subjects after testing of 1408 family members. The most common type of carrier risk change, from at risk to non-carrier status, accounted for 77% of the risk changes; 12% were a change to known carrier status from a lower risk. Sixty percent of persons with a carrier risk status change were not themselves tested; their risk status changed because of a relative's test result. Conclusions: Carrier risk status changes from uncertainty to certainty (that is, to carrier or to non-carrier) account for 89% of risk changes resulting from testing. These risk changes affect cancer prevention recommendations, most commonly reducing their burden. Current practices do not ensure that untested family members are informed about changes in their carrier risk status which result from mutation testing of their relatives.
引用
收藏
页码:591 / 596
页数:6
相关论文
共 24 条
  • [1] Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC):: A prospective follow-up study
    Aktan-Collan, K
    Haukkala, A
    Mecklin, JP
    Uutela, A
    Kääriäinen, H
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (04) : 608 - 611
  • [2] Benkendorf JL, 1997, AM J MED GENET, V73, P296, DOI 10.1002/(SICI)1096-8628(19971219)73:3<296::AID-AJMG13>3.0.CO
  • [3] 2-E
  • [4] BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
    Berry, DA
    Iversen, ES
    Gudbjartsson, DF
    Hiller, EH
    Garber, JE
    Peshkin, BN
    Lerman, C
    Watson, P
    Lynch, HT
    Hilsenbeck, SG
    Rubinstein, WS
    Hughes, KS
    Parmigiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2701 - 2712
  • [5] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2
    Burke, W
    Daly, M
    Garber, J
    Botkin, J
    Kahn, MJE
    Lynch, P
    McTierman, A
    Offit, K
    Perlman, J
    Petersen, G
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12): : 997 - 1003
  • [6] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .1. Hereditary nonpolyposis colon cancer
    Burke, W
    Petersen, G
    Lynch, P
    Botkin, J
    Daly, M
    Garber, J
    Kahn, MJE
    McTiernan, A
    Offit, K
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11): : 915 - 919
  • [7] Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers
    Hartmann, LC
    Sellers, TA
    Schaid, DJ
    Frank, TS
    Soderberg, CL
    Sitta, DL
    Frost, MH
    Grant, CS
    Donohue, JH
    Woods, JE
    McDonnell, SK
    Vockley, CW
    Deffenbaugh, A
    Couch, FJ
    Jenkins, RB
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (21): : 1633 - 1637
  • [8] Julian-Reynier C, 2000, AM J MED GENET, V94, P13, DOI 10.1002/1096-8628(20000904)94:1<13::AID-AJMG4>3.0.CO
  • [9] 2-T
  • [10] Lynch HT, 1999, CANCER, V86, P2449, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2449::AID-CNCR1>3.0.CO